Xspray Pharma gets go-ahead from the Swedish MPA for clinical study
Xspray Pharma has obtained approval from the Swedish Medical Products Agency (MPA) to carry out a previously announced clinical study of the formulation of the company’s product candidate HyNap-Dasa. The study is part of Xspray’s clinical program and will be completed during the third quarter. The objective is to confirm the bioequivalence of the optimized formulation developed by Xspray, based on the company’s patented RightSize-technology.“We are pleased with the progress of the project and following the decision of the MPA, we can now proceed with our plan for clinical studies,”